CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Study of Amrubicin in Relapsed or Refractory Thymic Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01364727
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:20.080909+00:00
Published At: 2017-03-14T00:00:00+00:00
Record Updated At: 2019-04-16
Results Posted At: 2017-03-14
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Thymoma", "Thymus Cancer", "Thymic Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2019-04-16"
protocolSection.identificationModule.nctId: "NCT01364727"
protocolSection.identificationModule.officialTitle: "A Phase II Study of Amrubicin in Relapsed or Refractory Thymic Malignancies"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2017-03-14"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.